Free β-human Chorionic Gonadotropin, Total Human Chorionic Gonadotropin and Maternal Risk of Breast Cancer

Toriola, Adetunji T.; Tolockiene, Egle; Schöck, Helena; Surcel, Heljä‐Marja; Zeleniuch‐Jacquotte, Anne; Wadell, Göran; Toniolo, Paolo; Lundin, Eva; Grankvist, Kjell; Lukanova, Annekatrin

doi:10.2217/fon.13.208

Cited by 6 publications

(2 citation statements)

References 32 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, consistent with the comparable NSMC study (2), we measured total hCG, a composite of intact and free hCG subforms. Total, free β-hCG, and the ratio of total to free β-hCG were similarly associated with risk in a small (n=159 cases), subsequent investigation among a subset of the cases in the NSMC (27) suggesting no meaningful difference by isoform.…”

Section: Discussionmentioning

confidence: 90%

Human Chorionic Gonadotropin Does Not Correlate with Risk for Maternal Breast Cancer: Results from the Finnish Maternity Cohort

et al. 2017

Self Cite

View full text Add to dashboard Cite

Human chorionic gonadotropin (hCG) is necessary for the maintenance of early pregnancy and promotes normal breast cell differentiation. Administered hCG reduces risk of carcinogen-induced breast cancer in animal models, and higher circulating hCG concentrations were associated with significantly lower long-term risk of breast cancer in a prior nested case-control study. In this study, we investigated early pregnancy hCG concentrations and subsequent breast cancer risk. We conducted a nested case-control study with 1,191 cases and 2,257 controls (matched on age and date at blood collection) in the Finnish Maternity Cohort (FMC), a cohort with serum samples from 98% of pregnancies registered in Finland since 1983. This study included women with a serum sample collected early (<140 days gestation) in their first pregnancy resulting in a live, term birth. Breast cancer cases were identified via the Finnish Cancer Registry. Age at breast cancer diagnosis ranged from 22–58 years (mean: 41 years). hCG was measured using a solidphase competitive chemiluminescence assay. Odds ratios (ORs) were calculated using conditional logistic regression. We observed no association between hCG and breast cancer risk, overall (Quartile 4 vs. 1, OR: 1.14 95% confidence interval [0.94–1.39]), by estrogen and progesterone receptor status, or by ages at first term birth or diagnosis. Associations did not differ by time between pregnancy and diagnosis (e.g., <5 years, ORQ4 vs. Q1: 1.10 [0.64–1.89]; ≥ 15 years, ORQ4 vs. Q1: 1.36 [0.86–2.13]; pheterogeneity=0.62). This large prospective study does not support an inverse relationship between early pregnancy serum hCG concentrations and breast cancer risk.

show abstract

Section: Discussionmentioning

confidence: 90%

Human Chorionic Gonadotropin Does Not Correlate with Risk for Maternal Breast Cancer: Results from the Finnish Maternity Cohort

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…A prediction of metastatic outgrowth and therapy response and monitoring was promoted by the group of Francia et al in 2008 (77). Furthermore, it was shown that there was no difference in the significance of total hCG and free β-subunit of hCG, as both could be related to maternal breast cancer risk (78). Recently it could even be demonstrated that hCG promotes normal breast cell differentiation in animal models, and administration of hCG or generally higher hCG levels prevent occurrence of breast cancer development in mice, but no inverse correlation between pregnancy and reduced breast cancer risk was shown (79).…”

Section: Role Of Hcg In Breast Cancer Hcg As a Tumor Markermentioning

confidence: 99%

The importance of hCG in human endometrial adenocarcinoma and breast cancer

et al. 2017

View full text Add to dashboard Cite

Human chorionic gonadotropin (hCG) is a peptide hormone which plays an important role during pregnancy. But its impact is not limited to pregnancy; it also influences tumor formation and metastatic outgrowth, especially in endometrial adenocarcinoma and breast cancer. This review summarizes what has been written in the literature about the role of hCG as a tumor marker in these 2 gynecological malignancies and also about the signal transduction pathways in which hCG is involved. HCG can, on the one hand, be a marker for the progression of a malignant disease, and on the other hand, it may be a point for therapeutical intervention, so further research into this molecule would be very much worthwhile.

show abstract

Maternal reproductive hormones and angiogenic factors in pregnancy and subsequent breast cancer risk

Cornish

Staff

Boyd³

et al. 2018

Cancer Causes Control

View full text Add to dashboard Cite

Purpose: Breast cancer risk associated with pregnancy characteristics may be mediated by maternal hormones or angiogenic factors. Methods: We conducted a prospective breast cancer case-control study among women in the Avon Longitudinal Study of Parents and Children (ALSPAC) and Norwegian Mother and Child Cohort Study (MoBa) related to maternal pregnancy prolactin (n=254 cases and 374 controls), placental growth factor (PlGF, n=252 and 371), soluble fms-like tyrosine kinase-1 (sFlt-1, n=118 and 240) and steroid hormone concentrations (ALSPAC only, n=173 and 171). Odds ratios (OR) and 95% confidence intervals (CI) for a 1 SD change in analytes were estimated using unconditional logistic regression with matching factors (cohort, mother’s birth year, serum/plasma, blood collection timing) and gestational age. Results: Breast cancer ORs (95% CI) were 0.85 (0.51–1.43) for estradiol, 0.86 (0.67–1.09) for testosterone, 0.89 (0.71–1.13) for androstenedione, 0.97 (0.71–1.34) for hCG, 0.93 (0.75, 1.15) for prolactin, 1.00 (0.78–1.27) for PlGF and 1.91 (1.00–3.65 ALSPAC) and 0.94 (0.73–1.21 MoBa) for sFlt-1, and were similar adjusting for potential confounders. Results were similar by blood collection timing, parity, age at first birth or diagnosis, and time between pregnancy and diagnosis. Conclusion: These data do not provide strong evidence of associations between maternal hormones or angiogenic factors with subsequent maternal breast cancer risk.

show abstract

Free β-human Chorionic Gonadotropin, Total Human Chorionic Gonadotropin and Maternal Risk of Breast Cancer

Cited by 6 publications

References 32 publications

Human Chorionic Gonadotropin Does Not Correlate with Risk for Maternal Breast Cancer: Results from the Finnish Maternity Cohort

Human Chorionic Gonadotropin Does Not Correlate with Risk for Maternal Breast Cancer: Results from the Finnish Maternity Cohort

The importance of hCG in human endometrial adenocarcinoma and breast cancer

Maternal reproductive hormones and angiogenic factors in pregnancy and subsequent breast cancer risk

Contact Info

Product

Resources

About